Caris Life Sciences Presents Six Multiomics Studies at ESMO 2025 Spanning Nine Cancer Types
Key Insights
Caris Life Sciences (search) will present six collaborative studies at ESMO 2025 in Berlin, showcasing multiomics research across nine tumor types including colorectal, gastric, breast, pancreatic, head & neck, prostate, urothelial, renal, and biliary tract cancers.
The studies were conducted with more than 25 leading cancer centers across the U.S., Europe, and Japan, demonstrating how integrated profiling, subtyping, and biomarker discovery are driving more informed treatment decisions.
Research presentations include investigations into mismatch repair deficiency (search) mechanisms, early-onset cancer (search) analysis, and transcriptomic-based therapeutic response prediction in various cancer subtypes.
Caris Life Sciences (search) will unveil six collaborative studies at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany from October 17-21, 2025, highlighting the transformative power of multiomics in precision cancer care. The research spans nine tumor types and demonstrates how integrated profiling, subtyping, and biomarker discovery are driving more informed treatment decisions and improving patient outcomes.
The six studies were conducted in collaboration with more than 25 leading cancer centers across the U.S., Europe, and Japan, including members of the Caris Precision Oncology Alliance (search). The research will be featured across multiple formats, including one oral "Proffered Paper," one mini-oral and four poster presentations.
Advancing Precision Oncology Through Multiomics
The studies highlight Caris' continued leadership in applying next-generation sequencing (WES and WTS), immunohistochemistry (IHC) and real-world clinico-genomic data to uncover actionable insights. Tumor types represented include colorectal, gastric, breast, pancreatic, head & neck, prostate, urothelial, renal, and biliary tract cancers.
"By integrating real-world data, advanced sequencing and biomarker discovery, we're refining cancer subtyping and treatment decisions to improve patient outcomes across numerous cancer types," said Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris. "ESMO provides an international stage to share these insights and accelerate the future of personalized cancer care."
Key Research Presentations
The oral "Proffered Paper" presentation will focus on "The Mechanism of Mismatch Repair Deficiency (search) (MMRd) Informs Survival Outcomes Derived from Immune Checkpoint Blockade (search) (ICB) Across MMRd Solid Tumors," scheduled for Saturday, October 18, 2025.
The mini-oral presentation will cover "Comprehensive Multi-Omics Analysis of Early-Onset Cancer (search): Insights from the MONSTAR-SCREEN-2 Experience," also on Saturday, October 18, 2025.
Four poster presentations will address diverse topics including the impact of androgen deprivation therapy (search) on KLK2 (search) mRNA expression in prostate cancer (search), optimization of immunotherapy (search) in mismatch repair-deficient colorectal cancer (search), transcriptomic-based prediction of therapeutic response in metastatic RAS (search)-mutant colorectal cancer, and NOTCH (search) pathway dynamics in head and neck squamous cell carcinoma (search).
Collaborative Research Network
The Caris Precision Oncology Alliance (search) consists of 97 cancer centers, academic institutions, research consortia and healthcare systems, including 45 NCI-designated cancer centers, all collaborating to advance precision oncology and biomarker-driven research. Caris and POA members collaborate to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers, aiming to improve clinical outcomes for cancer patients.
Technology Platform
Caris Life Sciences (search) operates as a patient-centric, next-generation AI TechBio company that has created a large-scale, multimodal clinico-genomic database through comprehensive molecular profiling using Whole Exome and Whole Transcriptome Sequencing. The company applies advanced AI and machine learning algorithms at scale to analyze and unravel the molecular complexity of disease, providing a differentiated platform for precision medicine diagnostic solutions.